Thank you, Jaime.
the a first COVID-XX activities, of Before we to discussion result pandemic. begin are I'd quarter the experiencing globally, times of challenging we to the as take our address like a moment
to thoughts been wellness those all who go have impacted and directly condolences by Our loved health has or illness. and whose out ones lost the
a also many We're learning era in virtually life. business new in and We're facing conduct family importance of and and of friends, ways unforeseen challenges our connected staying way to living colleagues. new the to daily with disruptions
also our of diligently unprecedented truly facing that and and be testing the treatments. development We expedite an to to test times hopeful remain we're industry We're that working proud part resilience. is of COVID-XX
multinational a other of working you to each accustomed and conducting of in environment we're meet fortunate able being as not exception were organization to with many normal. virtual as the as travel Achieve and business with a to
safety our number to will our Phase and providers COVID-XX of the trial The of participants, course one continue X health initiation of healthcare program. are We evaluating our the impact carefully clinical priority. be of development and employees on
such disease, so. help of to for as in Given of is conditions, to We more important with do ever quit. them potential cytisinicline COVID-XX in it to smokers than now pulmonary the believe pre-existing impacts individuals the
clinical in manner sites Phase we of continue to healthcare a in to our trial is trial anticipate our this trial to initiation second financing subject course and year. confidence participants is CRO, and the of to In in this addition conduct ORCA-X first that our ability of safe half the and to our X This providers.
perspective, weeks now cytisinicline to requested in ORCA-X regulatory have a and submitted for X FDA not did non-clinical XX trial. Phase all upcoming From of we the the allowing both treatment We data when X the observe initiate. Subject these any treatment evaluating trial signals Phase in new studies. safety XX be FDA, or non-clinical the ready will by or review final toxicology of to XX either X to
a And reminder, the the three, treatment of the simplification X and durable evaluation Number leading As only of three ease of the three schedule higher number address duration ORCA-X extension given expected times efficacy the will X of cytisinicline, number daily, one, of dose factors. use. and dosing milligram two, to yield key the XX more results. better weeks to the to trial
to X the not period measure ORCA-X patients could abstinence, will XX day of with continuous significant receiving the have of period It the to possible us X treatment in a extension endpoint was dosing This weeks benefits. Phase allow the still in The X cytisinicline. primary of weeks are trials while trial.
in in results while documented quit treatment efficacy higher As literature, typically the on are patients measuring rates.
cytisinicline, to addiction. as treatment a Shifting towards for other nicotine opportunities
as users. funding grant and application for assists companies a cytisinicline an treatment that X for potential financing initiated discussed, an we agreement partnership Phase to we with cessation recently our FreeMind, submitted Through this clinical with for the life e-cigarette a vapers previously non-dilutive of study organization opportunities. As science and nicotine evaluate
users seeking study States. the at financing multi-center, this X double enroll controlled X randomized This nicotine blind throughout subjects will quit. first conducted Phase the If be United to placebo e-cigarette trial sites non-dilutive adult study will this approximately in is then granted, XXX daily
and e-cigarettes grow. of to number The users continues vapers
As in are reported the of XXXX US in Annals which the users the XX Internal XX. half under nearly of age alone of nearly Medicine has in reached million
as nicotine and these combustible vapes historically also e-cigarettes cigarettes remains safety many long addiction now reduction, sustain While have seeking are their been harm controversial. safer to viewed than term Since the products vapers quit completely.
XXX explore recently vapers We IQVIA of approximately e-cigarettes. interesting with quitting. in vapes users To conducted survey a or nicotine further
even – prescription next that quit vape who indicated to try within product those only to vaping roughly new them they be XX will that within a do to intended specifically they to next months. [ph] nicotine, Looking months, the help X so. the at X quit Of intend XX% that extremely stated sooner XX individuals approximately to half likely
Ending nicotine grant believe the of the be the good. could quit outcomes users a approval and option for vapers drug and study, prescription new to cytisinicline who are first ready for the offering we e-cigarettes
I call on discussion, to the give brief timing study. to for the RAUORA John turn want the our I of before Now over update financial a
population. may of to Professor you trial Walker in by Innovation. the being effectiveness the study Health is Natalie As and led The safety, efficacy varenicline and New cost a of single to cytisinicline is recall, Māori the non-inferiority investigator randomized conducted Zealand Assistant controlled evaluate blind, indigenous an this compared trial National Institute
the safety effective whether first the this determine how as population. the to profiles is eagerly in head and at as to is varenicline head insights The as provide results cytisinicline we’ll evaluation least to RAUORA of compare awaited, trial are as
presentation medical applaud efforts We conducting in submitted later a trial challenging year. real the Walker's and data the this Dr conference expect for be world to at
first over results. our discuss turn the on to to call now John quarter financing recent the I'll
